Additionally, resistance to EGFR‐TKIs mediated by c‐MET amplification leads to the upregulation of PD‐L1 expression in NSCLC cells through the PI3K/AKT and MAPK signaling pathways. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.